

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

INTEGRATED BIOPHARMA INC

Form 8-K

August 05, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2004

Integrated BioPharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-28876

22-2407475

(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation or organization) Identification No.)

225 Long Avenue
Hillside, New Jersey

07205

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (973) 926-0816

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure.

On August 5, 2004, Integrated BioPharma, Inc., a Delaware corporation (the "Company"), issued a press release stating that Paxis Pharmaceuticals, a subsidiary wholly-owned by the Company, has made its initial GMP Paclitaxel API shipment. The press release is attached as an exhibit to this Report.

Item 7. Financial Statements and Exhibits

(c) Exhibits.

Exhibit No. Description

99.1 Press Release issued by Integrated BioPharma, Inc. on August 5, 2004

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 5, 2004

INTEGRATED BIOPHARMA, INC.

By: /s/ Eric Friedman
Eric Friedman
Vice President and Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release issued by Integrated BioPharma, Inc. on August 5, 2004